Legal & General Group Plc Has $30.64 Million Stock Position in BioNTech SE Sponsored ADR $BNTX

Legal & General Group Plc boosted its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 321,111 shares of the company’s stock after buying an additional 9,528 shares during the quarter. Legal & General Group Plc’s holdings in BioNTech were worth $30,636,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BNTX. Royal Bank of Canada boosted its stake in BioNTech by 95.9% in the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after buying an additional 3,514 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in BioNTech in the first quarter valued at about $167,000. Russell Investments Group Ltd. boosted its stake in BioNTech by 368,800.0% in the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after buying an additional 11,064 shares in the last quarter. Natixis acquired a new stake in BioNTech in the second quarter valued at about $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in BioNTech by 2.9% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock valued at $52,416,000 after buying an additional 13,788 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the transaction, the chief operating officer directly owned 399,387 shares in the company, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company’s stock.

BioNTech Price Performance

BioNTech stock opened at $95.95 on Friday. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $24.26 billion, a PE ratio of -16.32 and a beta of 1.36. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The stock has a 50-day moving average price of $94.46 and a two-hundred day moving average price of $99.49.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The firm had revenue of $1.06 billion during the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. Analysts expect that BioNTech SE Sponsored ADR will post -4.71 EPS for the current year.

BioNTech declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

BNTX has been the topic of several research analyst reports. BMO Capital Markets reduced their price objective on BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 11th. Berenberg Bank reduced their price objective on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Morgan Stanley raised their price objective on BioNTech from $125.00 to $126.00 and gave the company an “overweight” rating in a research note on Friday, April 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of BioNTech in a research note on Tuesday, March 17th. Finally, Canaccord Genuity Group reduced their price objective on BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.56.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.